Glycopyrronium bromide/formoterol

Glycopyrronium bromide/formoterol, sold under the brand name Bevespi Aerosphere, is a combination medication for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[2][3] It is a combination of glycopyrronium bromide and formoterol. It is inhaled.[2][3]

Glycopyrronium bromide/formoterol
Combination of
Glycopyrronium bromideMuscarinic anticholinergic
FormoterolLong-acting β2 agonist (LABA)
Clinical data
Trade namesBevespi Aerosphere
AHFS/Drugs.comConsumer Drug Information
License data
Pregnancy
category
  • US: C (Risk not ruled out) [1]
    Routes of
    administration    		Inhalation
    ATC code
    Legal status
    Legal status
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Identifiers
    UNII
    KEGG

    The most common side effects include headache, nausea (feeling sick), muscle spasms and dizziness.[3]

    Glycopyrronium bromide is a muscarinic receptor antagonist.[3] This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs.[3] Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open.[3]

    Formoterol is a long-acting beta-2 agonist.[3] It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways.[3] When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open.[3]

    Medical uses

    Glycopyrronium bromide/formoterol is indicated as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).[3]

    History

    Glycopyrronium bromide/formoterol was approved for medical use in the United States in April 2016,[4] and in the European Union in December 2018.[3]

    It is marketed by AstraZeneca.[2][3]

    References
    1. "Formoterol / glycopyrrolate (Bevespi Aerosphere) Use During Pregnancy". Drugs.com. 13 June 2019. Retrieved 8 May 2020.
    2. "Bevespi Aerosphere- glycopyrrolate and formoterol fumarate aerosol, metered". DailyMed. 29 May 2019. Retrieved 8 May 2020.
    3. "Bevespi Aerosphere EPAR". European Medicines Agency (EMA). 18 October 2018. Retrieved 8 May 2020. This article incorporates text from this source, which is in the public domain.
    4. "Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) Inhalation Aerosol". U.S. Food and Drug Administration (FDA). 16 February 2018. Retrieved 8 May 2020.

    Further reading
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.